Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.54 |
| ▸ | IKZF2 | Q9UKS7 | 12/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.48 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
| ▸ | WIZ | O95785 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25627458 | 1.00 | CRBN (0.54) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL25627420 | 0.98 | CRBN (0.52) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL25627398 | 0.93 | CRBN (0.54) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL25627428 | 0.93 | CRBN (0.51) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL31403666 | 0.92 | CRBN (0.65) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL23980467 | 0.92 | CRBN (0.65) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL25627463 | 0.91 | CRBN (0.49) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL25627462 | 0.91 | CRBN (0.56) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL23980574 | 0.90 | CRBN (0.63) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL25627400 | 0.90 | CRBN (0.52) | CRBNIKZF2CSNK1A1GSPT1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167081-A1 | 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167081-A1 | 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2021222542-A1 | 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167081-A1 | 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS | IKZF1, IKZF3, IKZF2 | CRBN 18/4885IKZF2 3/4885CSNK1A1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.